Brand Institute, announced its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide. Bavdegalutamide, also referred to as ARV-110, was published as a recommended INN in April of 2022. The product was granted fast-track designation by the FDA in May of 2019 for the treatment of metastatic castration-resistant prostate cancer.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.84 USD | -0.89% | -7.43% | -20.72% |
05-23 | Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress | CI |
05-16 | Sector Update: Health Care Stocks Steady Premarket Thursday | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.67% | 2.27B | |
+14.09% | 118B | |
+13.62% | 106B | |
-2.04% | 24.28B | |
+0.79% | 21.96B | |
-9.21% | 18.16B | |
-42.12% | 16.37B | |
-17.30% | 15.56B | |
+5.82% | 13.63B | |
+30.35% | 12.27B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Brand Institute Partners on Nonproprietary Name for Novel Protein Degrader Under Development by Arvinas, Inc